- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00711958
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
August 4, 2017 updated by: Sandoz
Double-blind, Randomized, Multicenter, Clinical Phase III Study to Evaluate the Efficacy and Safety of HX575 for the Treatment of Chemotherapy Associated Anemia in Cancer Patients
This is a randomized, double-blind, multicenter clinical phase III study involving about 105 cancer patients aged >18 years who are receiving palliative chemotherapy and who are suffering from chemotherapy associated anemia.
A standard treatment group (ERYPO®) will be included to provide a reference reflecting current standard medical practice.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Eligible patients were randomized to one of two different treatment groups (EPO HEXAL or ERYPO) in a 2:1 ratio.
Patients received double-blind treatment for a period of 12 weeks.
Following randomization the patients were treated subcutaneously with a dose of 150 IU/kg body weight of study drug three times per week.
Dose adjustments to 300 IU/kg body weight three times per week were to be done if hemoglobin (Hb) increased <1.0 g/dL or the reticulocyte count increased <40,000 /μl after 4 weeks or if Hb increased <2.0 g/dL after 8 weeks of treatment.
The primary endpoint was the Hb response in the EPO HEXAL group during weeks 5-12 of the study defined as absolute increase in Hb value of 2.0 g/dL from the mean value of the screening/baseline period in the absence of red blood cell transfusion during the preceding 4 weeks.
For that purpose, Hb levels were measured at the weekly study visits by a central laboratory.
Further parameters of treatment efficacy, safety and tolerability were recorded.
Study Type
Interventional
Enrollment (Actual)
114
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Augsburg, Germany, 86150
- Gemeinschaftspraxis Drs. Brudler, Heinrich, Bangerter
-
Bad Soden, Germany, 65812
- Gemeinschaftspraxis mit Schwerpunkt Hämatologie und Internistische Onkologie
-
Berlin, Germany, 10365
- Poliklinik am Paritätischen Krankenhaus
-
Berlin, Germany, 10367
- Schwerpunktpraxis für Brustkrankheiten und Gynäkologische Onkologie
-
Berlin, Germany, 14195
- Oskar-Helene-Heim
-
Freiburg, Germany, 79106
- Praxis Drs. Marschner, Zeiss, Kirste
-
Luckenwalde, Germany, 14943
- DRK-Krankenhaus
-
Munich, Germany, 80637
- Praxis für Onkologie
-
Munich, Germany, 81925
- Praxis Drs. Kowolik/Prechtl
-
Nürnberg, Germany, 90419
- Klinikum Nürnberg, 5. Medizinische Klinik Haus 12, Zimmer Nr. 13
-
Stuttgart, Germany, 70376
- Robert-Bosch-Krankenhaus
-
Stuttgart, Germany, 70173
- Gemeinschaftspraxis
-
Tübingen, Germany, 72076
- Universitätsklinikum Tübingen Medizinische Klinik 1
-
Velbert, Germany, 42551
- Gemeinschaftspraxis für internistische Onkologie
-
Weiden, Germany, 92637
- Praxis für internistische Onkologie
-
-
-
-
-
Cluj-Napoca, Romania, 400015
- Oncologic Institute
-
Oradea, Romania, 410032
- Country hospital Oradea
-
Satu-Mare, Romania, 440192
- County Hospital Satu-Mare
-
Timisoara, Romania, 300239
- Oncomed SRL Timisoara
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with a confirmed diagnosis of solid tumors
- Patients who receive cyclic palliative chemotherapy with a cycle duration of 1 -4 weeks (for at least 12 weeks) during the study
- Patients with chemotherapy associated anemia (hemoglobin < 10.0 g/dl at screening)
- Life expectancy of at least 6 months Age: > 18
- Eastern Cooperative Oncology Group performance status of 0, 1 or 2
- Serum ferritin greater or equal to 100 µg/l and/or saturated transferrin levels greater or equal to 20 %
- Adequate renal function (serum creatinine below or equal to 2.0 mg/dl)
- Adequate hepatic function (bilirubin < 1.5 times upper limit of normal range
- Patients with ability to follow study instructions, likely to complete all required visits and able to perform the quality of life assessment
- Written informed consent of the patient
Exclusion Criteria:
- Patients who receive curative intended chemotherapy
- Known primary or metastatic malignancy of the central nervous system
- Known primary or metastatic malignancy of bone marrow
- Primary hematologic disorder (e.g. myelodysplastic syndrome, sickle cell anemia, hematological malignancy, acute leukemia)
- Thrombotic events during the last 6 months
- Suspicion or known PRCA (pure red cell aplasia)
- Transfusion of white blood cells or packed red blood cells (more than 2 packs) within 4 weeks and any transfusion of white blood cells or packed red blood cells within 2 weeks prior to randomization (visit 0)
- Anemia due to overt bleeding or hemolysis within 2 weeks before screening
- Erythropoietin or Darbepoietin therapy within 8 weeks before screening, including any investigational form of erythropoietin (e.g. gene-activated erythropoietin, novel erythropoiesis stimulating protein)
- Radiation therapy during the study, radiation therapy induced anemia
- Therapy with cyclosporine
- Chemotherapy which causes predictable treatment with peripheral-blood progenitor therapy, e.g. G-CSF
- Clinical evidence of current uncontrolled hyperparathyroidism (serum parathyroid hormone >1500 pg/mL)
- Major surgery within 14 days prior to randomization
- Treatment with antiepileptics within the last 5 years
- Previously diagnosed HIV or acute hepatitis infection
- Uncontrolled hypertension, defined as a diastolic blood pressure measurement >110mm Hg during the screening period
- History of congestive heart failure (NYHA class III, IV)
- Unstable angina pectoris, active cardiac disease, cardiac infarction during the last six months before screening
- Evidence of acute infectious disease or serious active inflammatory disease within four weeks before screening (Visit -1) or during the screening/baseline period
- Known allergy to one of the ingredients of the test or reference products or hypersensitivity to mammalian-derived products
- Pregnancy, breastfeeding women or women not using adequate birth control measures
- Patients who participate simultaneously in another clinical study or who have participated in a study in the month preceding the start of this study or previously randomized to this study (except studies with approved medications in an approved indication, with an approved dosing regimen including approved treatment combinations)
- Suspicion of any non-compliance
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HX575 epoetin alfa Hexal AG
HX575 (erythropoietin alfa of the Sponsor Hexal AG).
Eligible patients to be randomized in ratio 2:1 and to be subcutaneously treated (solution for injection (s.c.)) for 12 weeks with HX575 in pre-filled syringes.
The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range.
Application of the drug required at least once per week and allowed maximum three times per week.
|
1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
Other Names:
|
ACTIVE_COMPARATOR: ERYPO® Janssen-Cilag
ERYPO® Janssen-Cilag, Germany.
Eligible patients were treated subcutaneously (solution for injection (s.c.)) with ERYPO® (Janssen-Cilag, Germany) in pre-filled syringes for 12 weeks.The maximum weekly dose of HX575 was 300 IU/kg body weight to maintain hemoglobin levels in the therapeutic range.
Application of the drug required at least once per week and allowed maximum three times per week.
|
1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of HX575 in the Treatment of Chemotherapy Associated Anemia
Time Frame: 5-12 weeks
|
Proportion of patients with a change in hemoglobin levels more than 2 g/dL under treatment with HX575, estimated between weeks 5-12.
|
5-12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2004
Primary Completion (ACTUAL)
July 1, 2005
Study Completion (ACTUAL)
December 1, 2005
Study Registration Dates
First Submitted
July 3, 2008
First Submitted That Met QC Criteria
July 8, 2008
First Posted (ESTIMATE)
July 9, 2008
Study Record Updates
Last Update Posted (ACTUAL)
September 5, 2017
Last Update Submitted That Met QC Criteria
August 4, 2017
Last Verified
August 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2003-31-INJ-11
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia
-
SanofiActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)United States, Austria, China, Denmark, Germany, Hungary, Italy, Spain, United Kingdom
-
SanofiTerminatedWarm Autoimmune Hemolytic Anemia (wAIHA)United Kingdom, Belgium, Netherlands, France, United States, Germany, Hungary, Italy
-
Hospital Universitario Dr. Jose E. GonzalezCompletedPernicious Anemia | Megaloblastic Anemia NosMexico
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSevere Aplastic Anemia | Idiopathic Aplastic Anemia | Moderate Aplastic Anemia Requiring Transfusions
-
Abdelwahed, Mai Mahmoud Mohamed, M.D.UnknownAnemia During PregnancyEgypt
-
University of California, DavisInstituto Mexicano del Seguro Social; Thrasher Research Fund; Mexican National... and other collaboratorsCompleted
-
Incyte CorporationActive, not recruitingWarm Autoimmune Hemolytic Anemia (wAIHA)Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
-
Peking Union Medical College HospitalRecruiting
-
Alexion PharmaceuticalsWithdrawnWarm Autoimmune Hemolytic AnemiaUnited States
Clinical Trials on HX575, solution for injection (s.c.)
-
SandozWithdrawnAnemia | Chronic Renal InsufficiencySpain, Romania, Bulgaria, France, Germany
-
Leti Pharma GmbHCompletedAllergic Rhinitis/Rhinoconjunctivitis +-Intermittent Asthma | Sensitization Against Betula Alba (Birch) PollenGermany
-
Boehringer IngelheimRecruitingNetherton SyndromeBelgium, United Kingdom, Australia, Germany, China, Malaysia, Japan, France, United States, Israel, Bulgaria, Italy, Switzerland, Austria, Netherlands, Portugal
-
10xBio, LLCActive, not recruitingSubmental FatUnited States
-
GlaxoSmithKlineCompleted
-
Novartis PharmaceuticalsRecruitingAutoimmunity, InflammationChina, United States, Spain, Czechia, Mexico, Bulgaria, Colombia, Brazil, Russian Federation, Guatemala, South Africa, Poland, India, Malaysia, Korea, Republic of, Greece
-
10xBio, LLCTherapeutics, Inc.Active, not recruitingSubcutaneous Fat DisorderUnited States
-
Ferring PharmaceuticalsCompleted
-
Mayo ClinicRecruitingLower Urinary Tract Obstructive Syndrome | Renal Failure Congenital | Congenital Renal Anomaly Nos | Renal Agenesis and DysgenesisUnited States
-
Novartis PharmaceuticalsActive, not recruitingPrimary Hypercholesterolemia or Mixed DyslipidemiaChina